Serum homocysteine and physical exercise in patients with Parkinson's disease

Psychogeriatrics

Volumn 11, Issue 2, 2011, Pages 105-112

  Nascimento, Carla Manuela Crispim ^a   Stella, Florindo ^a,b   Garlipp, Célia Regina ^b   Santos, Ruth Ferreira ^a,c   Gobbi, Sebastião ^a   Gobbi, Lilian Teresa Bucken ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c UNIVERSIDADE FEDERAL DO ABC   (Brazil)

Author keywords

Homocysteine; Parkinson's disease; Physical exercise

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANXIOLYTIC AGENT; BENSERAZIDE PLUS LEVODOPA; BIPERIDEN; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CHOLINESTERASE INHIBITOR; HOMOCYSTEINE; LEVODOPA; PRAMIPEXOLE; SELEGILINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; EXERCISE; FEMALE; FUNCTIONAL STATUS; HOMOCYSTEINE BLOOD LEVEL; HUMAN; MALE; MENTAL TEST; MINI MENTAL STATE EXAMINATION; MOTOR PERFORMANCE; PARKINSON DISEASE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RATING SCALE;

AGED; ANTIPARKINSON AGENTS; EXERCISE; FEMALE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; LEVODOPA; MALE; MATCHED-PAIR ANALYSIS; MENTAL STATUS SCHEDULE; MIDDLE AGED; PARKINSON DISEASE;

EID: 79959712587     PISSN: 13463500     EISSN: 14798301     Source Type: Journal    
DOI: 10.1111/j.1479-8301.2011.00356.x     Document Type: Article

References (44)

1. Siniscalchi A, Gallelli L, Mercuri NB, Ibbadu GF, De Sarro G. Role of lifestyle factors on plasma homocysteine levels in Parkison's disease patients treated with levodopa. Nutr Neurosci 2006; 9: 11-16.
2. Seshadri S, Beiser A, Selhub J etal. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346: 476-483.
3. Seshadri S, Wolf PA. Homocysteine and the brain: Vascular risk factor or neurotoxin? Lancet Neurol 2003; 2: 11.
4. Blandini F, Fancellu R, Martignoni E etal. Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease. Clin Chem 2001; 47: 1102-1104.
5. Yasui K, Kowa H, Nakaso K, Takeshima T, Nakashima K. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 2000; 55: 437-440.
6. Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa: Association with vascular disease. Arch Neurol 2003; 60: 59-64.
7. O'Suilleabhain PE, Sung V, Hernandez C etal. Elevated plasma homocysteine level in patients with Parkinson disease: Motor, affective, and cognitive associations. Arch Neurol 2004; 61: 865-868.
8. Muller T, Kuhn W. Cysteine elevation in levodopa-treated patients with Parkinson's disease. Mov Disord 2009; 24: 929-932.
9. O'Suilleabhain PE, Bottiglieri T, Dewey RB Jr, Sharma S, Diaz-Arrastia R. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease. Mov Disord 2004; 19: 1403-1408.
10. Joosten E. Homocysteine, vascular dementia and Alzheimer's disease. Clin Chem Lab Med 2001; 39: 717-720.
11. Di Santolo M, Banfi G, Stel G, Cauci S. Association of recreational physical activity with homocysteine, folate and lipid markers in young women. Eur J Appl Physiol 2009; 105: 111-118.
12. Herrmann M, Schorr H, Obeid R etal. Homocysteine increases during endurance exercise. Clin Chem Lab Med 2003; 41: 1518-1524.
13. Herrmann M, Wilkinson J, Schorr H etal. Comparison of the influence of volume-oriented training and high-intensity interval training on serum homocysteine and its cofactors in young, healthy swimmers. Clin Chem Lab Med 2003; 41: 1525-1531.
14. 12. Ann Nutr Metab 2003; 47: 114-118.
15. Joubert LM, Manore MM. Exercise, nutrition, and homocysteine. Int J Sport Nutr Exerc Metab 2006; 16: 341-361.
16. Hofman A, Ott A, Breteler MM etal. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997; 349: 151-154.
17. Breteler MM. Vascular risk factors for Alzheimer's disease: An epidemiologic perspective. Neurobiol Aging 2000; 21: 153-160.
18. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
19. Hoehn MH, Yahr MD. Parkinsonism: Onset, progression and mortality. Neurology 1967; 17: 427-442.
20. Fahn S, Elton RL. Unified Parkinson's disease rating scale. In: Fahn SMC, Calne DB, Lieberman A, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: MacMillan Health Care Information, 1987; 153-163.
21. Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FJ, Donaldson ML, eds. Third Symposium on Parkinson's Disease. Edinburgh: Livingstone, 1969; 152-157.
22. Folstein MF, Folstein SE, McHugh PR. 'Mini-Mental State'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
23. Roth M, Huppert FA, Montjoy CQ, Tym E. CAMDEX-R: The Cambridge examination for mental disorders of the elderly. Cambridge University Press 1999.
24. Zappacosta B, Persichilli S, Minucci A etal. Evaluation of a new enzymatic method for homocysteine measurement. Clin Biochem 2006; 39: 62-66.
25. Prins ND, Den Heijer T, Hofman A etal. Homocysteine and cognitive function in the elderly: The Rotterdam Scan Study. Neurology 2002; 59: 1375-1380.
26. Miller JW, Green R, Ramos MI etal. Homocysteine and cognitive function in the Sacramento Area Latino Study on Aging. Am J Clin Nutr 2003; 78: 441-447.
27. Miller JW. Homocysteine, folate deficiency, and Parkinson's disease. Nutr Rev 2002; 60: 410-413.
28. Khedr EM, Hamed SA, El-Shereef HK etal. Cognitive impairment after cerebrovascular stroke: Relationship to vascular risk factors. Neuropsychiatr Dis Treat 2009; 5: 103-116.
29. Haan MN, Miller JW, Aiello AE etal. Homocysteine, B vitamins, and the incidence of dementia and cognitive impairment: Results from the Sacramento Area Latino Study on Aging. Am J Clin Nutr 2007; 85: 511-517.
30. Ozer F, Meral H, Hanoglu L etal. Plasma homocysteine levels in patients treated with levodopa: Motor and cognitive associations. Neurol Res 2006; 28: 853-858.
31. Camicioli RM, Bouchard TP, Somerville MJ. Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients. Mov Disord 2009; 24: 176-182.
32. Huang CW, Chang WN, Lui CC etal. Impacts of hyper-homocysteinemia and white matter hyper-intensity in Alzheimer's disease patients with normal creatinine: An MRI-based study with longitudinal follow-up. Curr Alzheimer Res 2010; 7: 527-533.
33. Zoccolella S, dell'Aquila C, Abruzzese G etal. Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia. Mov Disord 2009; 24: 1028-1033.
34. Rodriguez-Oroz MC, Lage PM, Sanchez-Mut J etal. Homocysteine and cognitive impairment in Parkinson's disease: A biochemical, neuroimaging, and genetic study. Mov Disord 2009; 24: 1437-1444.
35. Obeid R, Herrmann W. Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett 2006; 580: 2994-3005.
36. Randeva HS, Lewandowski KC, Drzewoski J etal. Exercise decreases plasma total homocysteine in overweight young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87: 4496-4501.
37. Zinellu A, Sotgia S, Caria MA etal. Effect of acute exercise on low molecular weight thiols in plasma. Scand J Med Sci Sports 2007; 17: 452-456.
38. Nygard O, Refsum H, Ueland PM, Vollset SE. Major lifestyle determinants of plasma total homocysteine distribution: The Hordaland Homocysteine Study. Am J Clin Nutr 1998; 67: 263-270.
39. Duncan GE, Perri MG, Anton SD etal. Effects of exercise on emerging and traditional cardiovascular risk factors. Prev Med 2004; 39: 894-902.
40. Sotgia S, Carru C, Caria MA, Tadolini B, Deiana L, Zinellu A. Acute variations in homocysteine levels are related to creatine changes induced by physical activity. Clin Nutr 2007; 26: 444-449.
41. de Bree A, Verschuren WM, Blom HJ, Kromhout D. Lifestyle factors and plasma homocysteine concentrations in a general population sample. Am J Epidemiol 2001; 154: 150-154.
42. Takeda M, Okochi M, Tagami S, Tanaka T, Kudo T. Biological markers as outcome measures for Alzheimer's disease interventions: Real problems and future possibilities. Int Psychogeriatr 2007; 19: 391-400.
43. White AR, Huang X, Jobling MF etal. Homocysteine potentiates copper- and amyloid beta peptide-mediated toxicity in primary neuronal cultures: Possible risk factors in the Alzheimer's-type neurodegenerative pathways. J Neurochem 2001; 76: 1509-1520.
44. O'Suilleabhain PE, Oberle R, Bartis C, Dewey RB Jr, Bottiglieri T, Diaz-Arrastia R. Clinical course in Parkinson's disease with elevated homocysteine. Parkinsonism Relat Disord 2006; 12: 103-107.